| Chugai Seiyaku Kabushiki Kaisha Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129184 | SYSTEMIC CARNITINE DEFICIENCY GENE AND USES THEREOF - The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein. | 05-24-2012 |
| 20120121587 | ANTI-AXL ANTIBODY - An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the present invention have high antitumor activity, and are useful as agents for decreasing the AXL expression level, antitumor agents, and diagnostic agents for cancer. | 05-17-2012 |
| 20120071634 | Antibody Constant Region Variant - By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region. | 03-22-2012 |
| 20120065379 | Antibody Constant Region Variant - By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated. | 03-15-2012 |
| 20120015402 | Method of Proliferating Plasma Cells - An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. | 01-19-2012 |
| 20110306615 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF - According to the present invention, a compound represented by formula (I): | 12-15-2011 |
| 20110293602 | VEGF-LIKE FACTOR ANTIBODIES AND METHODS OF USE THEREOF - A novel human gene having a significant homology with a VEGF-C gene, a member of the VEGF family, has been isolated by the PCR method using primers designed based on the sequence of EST that is assumed to be homologous with the C-terminal region of the VEGF-C gene. Mouse and rat genes have been isolated based on the human gene isolated as above. A protein encoded by the above human gene has been isolated by introducing the gene into | 12-01-2011 |
| 20110282062 | 1-(2H)-ISOQUINOLONE DERIVATIVE - The present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof: | 11-17-2011 |
| 20110281271 | Oligoribonucleotide or Peptide Nucleic Acid Capable of Inhibiting Activity of Hepatitis C Virus - The present inventors focused on siE sequences that have been thought to show RNAi activity against HCV viral RNAs, and mainly selected the D5-50 and D5-197 regions present within the IRES region, and carried on the analysis. As a result, the present inventors successfully identified siRNA sequences that exhibit a more effective RNAi activity against hepatitis C virus RNAs. Furthermore, the siRNAs were demonstrated to have a significant inhibitory effect on HCV propagation in an in vivo system. | 11-17-2011 |
| 20110275703 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES - The present invention provides a compound represented by Formula (II): | 11-10-2011 |
| 20110245473 | Anti-IL-6 Receptor Antibody - The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations. | 10-06-2011 |
| 20110229506 | METHOD FOR CANCER IMMUNOTHERAPY - A novel compound of the formula (1): | 09-22-2011 |
| 20110229481 | CANCER-ASSOCIATED ANTIGEN ANALOGUE PEPTIDES AND USES THEREOF - First, to solve the problems of the present invention, the present inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients by using an experimental system that detects combinations of CD4 and IL-4 or IFNγ. Next, using analogue peptides of the core protein MUC16 of the ovarian cancer-associated antibody C125, the present inventors revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of patients and healthy subjects. Then, the present inventors analyzed the epitope for T cells in the core protein MUC16 of the ovarian cancer-associated antigen CA125, and determined the amino acid sequence FTLNFTITN (SEQ ID NO: 1) to be a shorter epitope. The present inventors further discovered that the analogue peptide OVCA11: GHTAPOPLLVPFTLNFTITN (SEQ ID NO: 11) is suitable for T cell activation. | 09-22-2011 |
| 20110229459 | ANTI-NR10 ANTIBODY AND USE THEREOF - The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases. | 09-22-2011 |
| 20110223133 | THERAPEUTIC AGENT FOR HEMATOPOIETIC TUMORS - An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24. | 09-15-2011 |
| 20110212901 | HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): | 09-01-2011 |
| 20110150869 | Neuroinvasion Inhibitor - The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice. | 06-23-2011 |
| 20110129459 | ANTI-NR10 ANTIBODY AND USE THEREOF - The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases. | 06-02-2011 |
| 20110111406 | ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY - The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen. | 05-12-2011 |
| 20110104157 | LIVER CANCER DRUG - A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent. | 05-05-2011 |
| 20110098450 | Antibody Molecules - The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions. | 04-28-2011 |
| 20110091907 | METHOD FOR DETECTION OF LIVER CANCER CELL USING ANTI-GLYPICAN-3 ANTIBODY - The present invention relates to an in-vitro immunoassay method for detecting the presence of liver cancer cells in a subject. In the method of the present invention, antigen retrieval treatment based on heat-induced epitope retrieval method and antigen retrieval treatment based on protease-induced epitope retrieval method can be combined in the detection of glypican 3 antigen expression in liver cancer tissues to thereby detect the difference in the expression level or expression pattern of the glypican 3 antigen by immunohistochemical staining method. This enables samples, which has been determined by the conventional HIER method as highly expressing glypican 3, to be graded according to the expression level of glypican 3. | 04-21-2011 |
| 20110087007 | Cytokine-Like Proteins - A full-length cDNA corresponding to an EST (AA418955), which does not show any homology to other proteins in the database but has a weak homology to G-CSF, has been successfully isolated by synthesizing primers based on the EST sequence, and effecting PCR-cloning from a human fetal spleen library. Sequencing of the thus-isolated cDNA and analysis of its structure revealed that the cDNA has typical characteristics of a factor belonging to the IL-6/G-CSF/MGF family. It is also found out that the culture supernatant of said sequence-transfected CHO cells shows a proliferation supporting activity towards bone marrow cells in the coexistence of kit ligand. | 04-14-2011 |
| 20110082284 | Gene overexpressed in cancer - Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer. | 04-07-2011 |
| 20110076275 | Method of Modifying Isoelectric Point of Antibody Via Amino Acid Substitution in CDR - The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions. | 03-31-2011 |
| 20110065149 | METHOD OF PRODUCING FUSED PROTEIN - Described herein is a polynucleotide encoding a fusion protein comprising two or more polypeptide domains and a polypeptide linker joining the domains, wherein the sequence of the polynucleotide encoding the polypeptide linker is selected such that when the mRNA transcribed from the polynucleotide is translated in a host cell transfected with the polynucleotide, the translation rate of the mRNA region encoding the polypeptide linker is slower than the translation rate of the mRNA region encoding the polypeptide domain immediately upstream thereof. Also provided are a vector transfected with the polynucleotide of the present invention so that the polynucleotide can be expressed in the host cell; a host cell transformed by that vector; and a process for producing a fusion protein comprising culturing the host cell, and recovering the fusion protein thus produced. | 03-17-2011 |
| 20110060146 | VITAMIN-D-LIKE COMPOUNDS - The present invention provides a compound represented by the following general formula (I): | 03-10-2011 |
| 20110059488 | Anti-MPL Antibodies - Anti-human Mpl antibodies were isolated and purified, and then anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were purified using genetic engineering techniques. Furthermore, the present inventors succeeded in humanizing anti-human Mpl sc(Fv)2. | 03-10-2011 |
| 20110044984 | Monoclonal Antibody Capable of Binding to Anexelekto, and Use Thereof - The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity. | 02-24-2011 |
| 20110033452 | Anti-Glypican 3 Antibody Having Modified Sugar Chain - An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent. | 02-10-2011 |
| 20110002922 | CELL GROWTH INHIBITORS CONTAINING ANTI-GLYPICAN 3 ANTIBODY - Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient. | 01-06-2011 |
| 20100329988 | Method for Identifying Within a Mammal a DNA Encoding A Physiologically Active Polypeptide - The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance. | 12-30-2010 |
| 20100329987 | Uses of Sperm Membrane Protein OBF - The present invention yielded unique monoclonal antibodies that reacted specifically only to sperms after acrosome reaction, and the antigens (OBFs) recognized by the antibodies were identified. The antibodies were found to inhibit fusion between mouse sperms and eggs. Furthermore, OBF gene-knockout mice were created and analyzed to clarify the in vivo functions of OBF. As a result, male OBF gene-knockout mice were shown to be infertile, and their sperms were shown to be able to bind to eggs, but had no fusion ability. | 12-30-2010 |
| 20100310556 | THERAPEUTIC AGENT FOR PRURITUS - The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus. | 12-09-2010 |
| 20100304401 | YS68 GENE INVOLVED IN PRIMITIVE HEMATOPOIESIS - A novel gene, dubbed “YS68”, involved in primitive hematopoiesis was successfully isolated from cDNA derived from mouse yolk sacs. In addition, a human gene corresponding to this gene was successfully isolated. Expression characteristics of these genes suggested their involvement in primitive hematopoiesis. The proteins of this invention and genes encoding the proteins may be utilized as tools for drug development against diseases, such as hematological disorders. | 12-02-2010 |
| 20100298542 | Modified Antibody Constant Region - The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics. | 11-25-2010 |
| 20100267571 | NOVEL METHOD FOR SPECIMEN PREPARATION, WHICH ENSURES PRESERVATION OF TISSUE MORPHOLOGY AND NUCLEIC ACID QUALITY - The present invention aims to develop a method for specimen preparation, which ensures the maintenance of both tissue morphology and nucleic acid quality (particularly RNA quality). The present invention further aims to prepare a specimen by this method, from which desired cells are then collected by microdissection and analyzed for gene expression. A method for specimen preparation from various frozen or unfrozen organs or tissues (excluding hard tissues) of the whole body, which comprises the following steps: 1) fixing a target organ or tissue with PFA fixative; and 2) embedding the same in paraffin by the AMeX method. | 10-21-2010 |
| 20100261917 | PROCESS FOR PRODUCING VITAMIN D DERIVATIVE USING PHOTOREACTION - There are provided a novel process for producing [{(5Z,7E)-(1S,3R,20S)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide, which process is characterized by irradiating a compound represented by the formula: | 10-14-2010 |
| 20100255007 | THERAPEUTIC AGENTS FOR GRAFT-VERSUS-HOST DISEASE COMPRISING INTERLEUKIN 6 RECEPTOR INHIBITOR AS ACTIVE INGREDIENT - The present invention provides a novel therapeutic agent for graft-versus-host disease (GVHD). | 10-07-2010 |
| 20100248359 | Anti-Glypican 3 Antibody - An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers. | 09-30-2010 |
| 20100247539 | Antibodies that Inhibit Transport Activity of Peptide Transporters - The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer. | 09-30-2010 |
| 20100247523 | Subtypes of humanized antibody against interleuken-6 receptor - As a subtype of humanized PM-1 antibody against interleukin-6 receptor (IL-6R), there is provided antibody sub-type (1) whose one heavy chain C terminus consists of Pro-NH | 09-30-2010 |
| 20100234276 | ERYTHROPOIETIN SOLUTION PREPARATION - The present invention relates to an erythropoietin-containing solution preparation containing a poloxamer and having a pH of 6.5 to 7.5. The present invention also relates to a method for quantifying a protein in a trace amount, the method including the following steps: binding a protein sample to a high-intensity fluorescent dye; separating a desired analyte from the obtained sample by an appropriate separation means; and quantifying the desired analyte and converting the amount of the analyte into the amount of the protein. | 09-16-2010 |
| 20100222427 | PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR PHOSPHATE - The present invention provides a pharmaceutical composition comprising: one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25° C. and at 70% relative humidity; and oseltamivir phosphate, wherein an amount of each of glucose and mannose contained in the sugars and sugar alcohols as impurities is 0.01% by weight or less. | 09-02-2010 |
| 20100218267 | Methods for Producing Antibodies - This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens. | 08-26-2010 |
| 20100210818 | NUCLEIC ACIDS ENCODING THE HUMAN ALEX1 PROTEIN - The present invention provides a novel protein containing an armadillo repeat, a gene encoding this protein, and production and use thereof. The present inventors identified a gene named ALEX1 encoding a human-derived novel armadillo repeat-containing protein. It was clarified that ALEX1 interacts with several proteins including insulin-degrading enzyme, presenilin-1, and JNK interacting protein 1. This gene shows significantly decreased expression in cancer cells. The protein ALEX1 and the gene encoding this protein are usable as tools in testing for diseases such as cancer and Alzheimer's disease and developing pharmaceutical agents. | 08-19-2010 |
| 20100197917 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS - Novel compounds composition capable of inhibiting TNFα and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds. | 08-05-2010 |
| 20100197676 | 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors - An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. | 08-05-2010 |
| 20100183595 | Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3 - Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells. | 07-22-2010 |
| 20100179326 | BENZAMIDE DERIVATIVE - Compounds having high angiogenesis inhibiting activity useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, e.g. cancer and cancer metastasis, are of formula (II), | 07-15-2010 |
| 20100174076 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS - Novel compounds composition capable of inhibiting TNFα and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds. | 07-08-2010 |
| 20100172899 | IgM Production by Transformed Cell and Method of Quantifying the Same - IgM can be obtained in the form of a pentamer by placing the genes encoding the H, L, and J chains on the same vector to transform appropriate host cells. The gene encoding the J chain may be introduced by co-transfection. When no J chain is expressed, the IgM is produced as a hexamer. The transformants obtained according to the present invention achieve a high yield of IgM. The present invention also provides methods which enable separation and quantification of polymeric IgM. | 07-08-2010 |
| 20100168430 | MULTIKINASE INHIBITOR - It is intended to provide a compound represented by the formula (1): | 07-01-2010 |
| 20100150927 | CELL DEATH INDUCER - An objective of the present invention is to provide an antibody having a high cell death-inducing activity. To solve the above-described problems, the present inventors immunized mice with cells expressing human HLA class IA and human β2 microglobulin (β2M) to obtain monoclonal antibodies. Screening of the obtained antibodies was performed to obtain ten clones of antibodies having a cell death-inducing activity. Analyses of these clones revealed that three of the clones (antibodies C3B3, C11B9, and C17D11), which have the α2 domain of the HLA class I antigen as an epitope, showed a stronger cytotoxic activity when crosslinked with an anti-mouse IgG antibody. Furthermore, when a C3B3 diabody was generated, this diabody was revealed to show a stronger anti-tumor effect compared with conventional diabodies of the 2D7 antibody, which is an HLA class IA antibody. | 06-17-2010 |
| 20100129355 | THERAPEUTIC AGENTS FOR OCULAR INFLAMMATORY DISEASE COMPRISING INTERLEUKIN 6 RECEPTOR INHIBITOR AS ACTIVE INGREDIENT - The present invention relates to therapeutic and/or prophylactic agents for ocular inflammatory disease, which comprise an interleukin 6 (IL-6) receptor inhibitor as an active ingredient. | 05-27-2010 |
| 20100093744 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES - The present invention provides a compound represented by Formula (II): | 04-15-2010 |
| 20100092461 | Remedy For Chemotherapy-Resistant Cancer Containing HLA Class I-Recognizing Antibody as the Active Ingredient and Use of the Same - The present invention describes therapeutic agents for chemotherapeutic agent-resistant cancers that include an HLA class I-recognizing antibody as an active ingredient. A further objective of the present invention is to provide methods for treating chemotherapeutic agent-resistant cancers that include the step of administering an HLA class I-recognizing antibody to a subject. It is herein demonstrated that cytotoxic activity due to C3B3 diabody is induced at a lower concentration in chemotherapeutic agent-resistant hematological tumor cell lines having high MDR1 and HLA class IA protein expression, than in their parent cell lines. It was also found that when the chemotherapeutic agent-resistant hematological tumor cell line is pretreated with a C3B3 diabody, cell injury associated with sole use of chemotherapeutic agent is enhanced and the amount of pharmaceutical agents taken up into cells are increased. More specifically, it was discovered that the C3B3 diabody exhibits anti-tumor activity on MDR1-expressing tumor cells having high HLA class I expression, and thereby is effective in overcoming drug resistance. | 04-15-2010 |
| 20100062010 | NOVEL PEPTIDE COMPOUND - A novel compound of the formula (1): | 03-11-2010 |
| 20100061986 | Chronic Rejection Inhibitor - The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody. | 03-11-2010 |
| 20100056510 | Macrocyclic Compound - The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: | 03-04-2010 |
| 20100055092 | Preventive or Remedy for Inflammatory Disease - The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications. | 03-04-2010 |
| 20100040600 | Agents for Promoting the Growth of Hematopoietic Stem Cells - The present inventors discovered that the administration of an agonistic minibody (VB22B sc(Fv)2) against the TPO receptor resulted in not only the induction of human megakaryocyte-specific differentiation (increase in platelet precursor cells), but also the engraftment of transplanted hematopoietic stem cells derived from human cord blood (CD34-positive cells) and significant increase in multi-lineage hematopoietic precursor cells. TPO and TPO receptor agonists can be used as agents for promoting the growth of CD34-positive hematopoietic cells or agents for promoting the engraftment of transplanted cells in the bone marrow, which can be effective when administered alone (without using G-CSF and erythropoietin in combination) after hematopoietic stem cell transplantation (in particular, cord blood transplantation). Furthermore, TPO and TPO receptor agonists can be used as agents for promoting the growth and/or differentiation of multilineage hematopoietic precursor cells and agents for promoting the recovery of multilineage hematopoiesis. | 02-18-2010 |
| 20100034811 | THERAPEUTIC AGENTS FOR DISEASES INVOLVING CHOROIDAL NEOVASCULARIZATION - The present inventors focused on the fact that inflammation at the subretinal macular area enhances choroidal neovascularization, and developed pharmaceutical agents that suppress initiation or advancement of neovascularization by angiogenic factors such as VEGF. More specifically, the present inventors revealed that administering anti-IL-6 receptor monoclonal antibodies to mice treated with laser photocoagulation inhibits the development of choroidal neovascularization. | 02-11-2010 |
| 20100021535 | LIGHT-STABILIZED SOFT CAPSULE FORMULATIONS - An object of the present invention is to provide a small-sized light-stabilized soft capsule formulation, which has a shell that ensures effective light shielding of an active ingredient encapsulated thereby. | 01-28-2010 |
| 20100015133 | Methods for Producing Polypeptides by Regulating Polypeptide Association - In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies. | 01-21-2010 |
| 20100003254 | Antibody Substituting for Function of Blood Coagulation Factor VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 01-07-2010 |
| 20100003245 | Remedy for Renal Disease - When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix. | 01-07-2010 |
| 20090326225 | Novel Process for the Preparation of Hexacyclic Compounds - This invention relates to novel processes for the preparation of compounds of the formula [1], | 12-31-2009 |
| 20090324589 | METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES - The present inventors discovered that the half-life in blood of an IgG antibody which is a polypeptide comprising an FcRn-binding domain can be controlled by controlling the surface charge through modification of residues exposed on the surface among residues in the variable regions of the IgG antibody. Antibodies whose half-life in blood had been controlled by the methods of the present invention were confirmed to actually retain the original activity. The methods of the present invention are widely applicable to polypeptides comprising an FcRn-binding domain, such as IgG antibodies, which are recycled via the FcRn salvage pathway regardless of the type of target antigen. | 12-31-2009 |
| 20090312554 | Novel Process for the Preparation of Hexacyclic Compounds - This invention relates to novel processes for the preparation of compounds of the formula [1], | 12-17-2009 |
| 20090297501 | Structural Isomers of sc(Fv)2 - Structural isomers in sc(Fv)2 compositions of anti-human Mpl antibody and humanized anti-human Mpl antibody were separated, and the obtained structural isomers were cleaved at their linkers to confirm that the structural isomers are of single chain diabody type and bivalent scFv type. In addition, the agonistic activities of these structural isomers were revealed to be significantly different. Furthermore, the present inventors discovered that the content ratio of the structural isomers in sc(Fv)2 compositions could be regulated by altering temperature, modifying lengths of the linkers of sc(Fv)2, or amino acids in their variable regions. | 12-03-2009 |
| 20090291076 | STABILIZED ANTIBODY-CONTAINING FORMULATIONS - The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof. | 11-26-2009 |
| 20090286724 | AGGREGABLE GLP-1 ANALOGUE AND SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION - The present invention provides a GLP-1 analogue having a high association-aggregability or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition to be used for preventing or treating diabetes, hyperglycemia, a diabetic complication caused by diabetes or hyperglycemia, or obesity, using the same. | 11-19-2009 |
| 20090280094 | Treatment of Ischemic Diseases Using Erythropoietin - Disclosed is a method for stimulating revascularization in a subject comprising the steps of:
| 11-12-2009 |
| 20090269335 | THERAPEUTIC AGENT FOR PROSTATE CANCER - The present inventors investigated the antitumor effects of anti-IL-6 receptor antibodies against prostate cancer. The result showed that the anti-IL-6 receptor antibodies had both in vivo and in vitro antitumor effects against prostate cancer. It was also revealed that the hPM1 antitumor effect is via IL-6 receptor. | 10-29-2009 |
| 20090264629 | STABILIZED PROTEIN-CONTAINING FORMULATIONS - Protein formulations containing a poloxamer as a surfactant, and methods for maintaining the biological activity in protein formulations without adding an antioxidant and for inhibiting the formation of foreign insoluble matters by adding a poloxamer as a surfactant. | 10-22-2009 |
| 20090263392 | METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES - The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies. | 10-22-2009 |
| 20090263384 | Agents for Suppressing the Induction of Cytotoxic T Cells - The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation. | 10-22-2009 |
| 20090258022 | ANTIBODIES TO BRAIN SPECIFIC MEMBRANE PROTEIN - A novel gene apparently encoding a transmembrane glycoprotein has been successfully isolated by constructing a cDNA library of 4 kb or above in size from mRNA expressed in human adult brain and analyzing the structures of the cDNAs contained within said library by the shotgun method. The novel gene shows brain-specific expression and the protein encoded by said gene has a typical PDZ binding motif. | 10-15-2009 |
| 20090247524 | HSP90 Inhibitor - Compounds represented by formula (1) shown below, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such compounds are provided. | 10-01-2009 |
| 20090220967 | Systemic Carnitine Deficiency Gene and Uses Thereof - The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein. | 09-03-2009 |
| 20090220500 | AGENTS FOR TREATING CARDIOPATHY - The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and suppressed myocardial MCP-1 expression in both the infarcted area and the non-infarcted area. Furthermore, echocardiography and histological examinations revealed that cardiac hypertrophy is also suppressed. | 09-03-2009 |
| 20090214535 | Pharmaceutical Compositions Containing sc(Fv)2 - The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction. | 08-27-2009 |
| 20090192108 | Gene overexpressed in cancer - Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer. | 07-30-2009 |
| 20090191591 | Taurine Transporter Gene - The present invention provides a method capable of producing a natural or recombinant protein at low cost. | 07-30-2009 |
| 20090181368 | METHOD OF DETECTING MYCOPLASMA - An object of the present invention is to provide a primer capable of detecting a mycoplasma | 07-16-2009 |
| 20090148534 | Process for producing water-soluble hyaluronic acid modification - The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction rate of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction rate as that of the conventionally known gel. | 06-11-2009 |
| 20090137609 | VITAMIN D-LIKE COMPOUND - The present invention provides a compound represented by the following general formula (I): | 05-28-2009 |
| 20090131639 | ANTIBODY-CONTAINING SOLUTION FORMULATIONS - Antibody-containing solution formulations including a sugar as a stabilizer. Said solution formulations can further include a surfactant as a stabilizer. | 05-21-2009 |
| 20090124660 | Piperidine Compounds Useful as Malonyl-CoA Decarboxylase Inhibitors - The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity. | 05-14-2009 |
| 20090118271 | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug - Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer of the present invention comprise a water-soluble prodrug represented by formula 1 described below, or a pharmaceutically acceptable salt, or a hydrate or solvate of the prodrug or pharmaceutically acceptable salt, | 05-07-2009 |
| 20090117097 | Stabilizer for Protein Preparation Comprising Meglumine and Use Thereof - An objective of the present invention is to provide methods for stabilizing proteins and methods for suppressing protein aggregation, which comprise the step of adding for suppressing protein aggregation, which comprise meglumine. Still another objective of the present invention is to provide pharmaceutical compositions comprising antibody molecules stabilized by meglumine, methods for producing the pharmaceutical compositions, and kits comprising the pharmaceutical compositions. | 05-07-2009 |
| 20090099090 | HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES - HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients. | 04-16-2009 |
| 20090098197 | CANCER VACCINE COMPRISING A CANCER ANTIGEN BASED ON THE PRODUCT OF A TUMOR SUPPRESSOR GENE WT1 AND A CATIONIC LIPOSOME - A cancer vaccine comprising a cancer antigen which comprises, as an active ingredient, the product of a tumor suppressor gene WT1, a partial peptide or a modified version thereof, and a cationic liposome. | 04-16-2009 |
| 20090083863 | p300 transgenic animal - The present invention relates to a transgenic animal wherein DNA encoding p300 and a promoter exerting its activity in myocardial cells are introduced, and a screening method using the same. | 03-26-2009 |
| 20090062219 | DRUGS FOR THE TREATMENT AND/OR PROPHYLAXIS OF GASTROPARESIS SYMPTOM - The present invention provides a therapeutic and/or preventive agent against gastroparesis symptom which is appropriate for continuous medication and which comprises a compound represented by formula (1): | 03-05-2009 |
| 20090061485 | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited - The present invention relates to a method of producing a recombinant protein, particularly an antibody, using a cell in which the function of a fucose transporter is inhibited, and it also provides a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed. | 03-05-2009 |
| 20090060907 | Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3 - Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells. | 03-05-2009 |
| 20090049561 | NON-HUMAN ANIMAL EXHIBITING BONE METASTASIS OF TUMOR CELLS - The present invention provides a non-human bone metastasis model animal in which tumor cells capable of inducing bone metastasis by peripheral administration have been introduced, and a method for producing the animal. The bone metastasis model animal in the present invention may be useful for understanding the biology of bone metastasis and developing novel therapeutic strategies for lung cancer patient with multi-organ metastases, including bone metastasis | 02-19-2009 |
| 20090035320 | Agents for Regulating Liver Regeneration/Repair - The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to agents for enhancing tissue regeneration and/or repair, with anti-PCI antibodies as active ingredients (particularly, anti-PCI antibodies with the action of neutralizing PCI (anti-PCI neutralizing antibodies)). | 02-05-2009 |
| 20090030195 | 1-(2H)-ISOQUINOLONE DERIVATIVE - The present invention provides a compound having high antitumor activity, which is useful for therapeutic and preventive agents effective for proliferative diseases such as cancer; a production method thereof; an intermediate compound useful for such production; and a pharmaceutical composition comprising such a compound. The present invention provides a compound represented by the formula (1): | 01-29-2009 |
| 20090022687 | Novel Pharmaceuticals That Use Anti-HLA Antibodies - The present inventors tested the effects of interferons on the expression of HLA-A in cells and cell injury caused by anti-HLA class I antibodies, by using a 2D7-DB antibody as an anti-HLA class I antibody and the IM-9 cell line as the cells to be tested. As a result, the expression of HLA-A was demonstrated to be upregulated by IFNα or IFNγ, Furthermore, WST-8 assays were performed to examine the cell viability when an interferon and an anti-HLA class I antibody were used in combination. As a result, cell death activity was found to be increased by the combination of 2D7-DB and IFNα or IFNγ. | 01-22-2009 |
| 20090005540 | Method For Removing Sialic Acid and Method For Producing Asialoerythropoietin - The object is to provide a method for removing a sialic acid that can be carried out simply at a low cost and a method for producing asialoerythropoietin using the same. The method for removing a sialic acid according to the present invention includes an acidifying and heating process of acidifying and heating a solution containing erythropoietin so as to remove a sialic acid bonded to an erythropoietin molecule. Further, the method for producing asialoerythropoietin according to the present invention includes a sialic acid removing process of removing a sialic acid bonded to an erythropoietin molecule by the method for removing a sialic acid according to the present invention. | 01-01-2009 |
| 20080318874 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes - A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): | 12-25-2008 |
| 20080306247 | ANTIBODY-CONTAINING SOLUTION FORMULATIONS - An antibody-containing solution formulation comprising an organic acid and a surfactant as stabilizers; a method for suppressing the formation of visible insoluble matter and/or insoluble particles due to the presence of metal ions in an antibody-containing solution formulation, which comprises adding an organic acid to the solution; a method for suppressing the formation of visible insoluble matter and/or insoluble particles during shaking and freezing-thawing of an antibody-containing solution, which comprises adding a surfactant to the solution; and a method for stabilizing an antibody-containing solution, which comprises adding an organic acid and a surfactant. | 12-11-2008 |
| 20080255342 | PROTEIN PURIFICATION METHOD - A method for removing contaminant DNA in a sample containing a physiologically active protein, which comprises the following steps:
| 10-16-2008 |
| 20080250514 | Expression Systems Using Mammalian Beta-Actin Promoter - Promoter activities were examined by comparing combinations of promoters and enhancers derived from various genes. A hybrid promoter comprising a combination of a CMV enhancer and a mammalian β-actin promoter, or the post-transcriptional regulatory region of the genomic sequence Woodchuck Hepatitis Virus (WPRE) and a mammalian β-actin promoter was found to be stronger than existing promoters. Furthermore, the activities of the β-actin promoters could be enhanced by coexpressing the oncogene product Ras, which is a transactivator. | 10-09-2008 |
